ScreenerHero

BANB Bachem Holding AG

SWX · CH · Healthcare · Biotechnology · bachem.com
79.25CHF-0.06%Mkt Cap: 6.78B $P/E: 40.03

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap6.78B USD
Enterprise Value6.97B USD
Revenue (TTM)808.65M USD
Gross Profit227.96M USD
Net Income (TTM)169.82M USD
Revenue/Share9.44 CHF
Last Price79.25 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.7K
CountryCH
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)40.03
P/E (Forward)25.75
PEG0.61
EV/EBITDA29.02
EV/Revenue8.62
P/S8.39
P/B4.12
EPS (TTM)1.98
EPS (Forward)3.08
52W Range
48.5286% of range84.10
52W High84.10 CHF
52W Low48.52 CHF
Profitability
Gross Margin28.74%
Oper. Margin16.59%
EBITDA Margin29.70%
Profit Margin21.41%
ROE10.20%
ROA7.06%
Growth
Revenue Growth4.30%
Earnings Growth0.00%
Cash Flow & Leverage
Operating CF309.95M USD
CapEx (TTM)375.94M USD
FCF Margin-29.24%
FCF Yield-3.49%
Net Debt178.65M USD
Net Debt/EBITDA0.74
Balance Sheet
Debt/Equity14.41
Current Ratio1.60
Quick Ratio0.46
Book Value/Sh19.24 CHF
Cash/Share0.69 CHF
Dividends
Fwd Div Rate0.90 CHF
Trail. Div Rate0.90 CHF
Div. Yield1.13%
5Y Avg Yield0.98%
Payout Ratio45.45%
Ex-Div DateMay 4, 2026
Pay DateMay 7, 2025
Splits
Last Split5:1
Split DateMay 5, 2022
Analyst Consensus
Rating—
Target (Mean)84.30 CHF
Upside (mean)+6.4%
Target Range50.00 CHF – 110.00 CHF
50.00+6.4% to mean110.00
# Analysts10
Ownership
Shares Out.74.94M
Float31.25M
Insiders0.25%
Institutions82.64%
Technical
SMA 5077.02 (+2.9%)
SMA 20070.28 (+12.8%)
Beta0.80
S&P 52W Chg14.58%
Avg Vol (30d)95.38K
Avg Vol (10d)86.78K
Technical Indicators
RSI (14)50.9
MACD1.1241
MACD Signal1.3748
MACD Hist.-0.2507
BB Upper84.20 CHF
BB Middle79.56 CHF
BB Lower74.93 CHF
BB Width11.65%
ATR (14)2.592 CHF
Vol Ratio (20d)0.58x